Neurochemistry International · 2019 · 27 citations · 19 references
MedicineNeurosciencePharmacologyMolecular NeuroscienceNeurochemistryNeuropharmacologyAstrocyte BiologyIron Chelation TherapyIron MetabolismNeurodegenerative DiseasesNeurodegenerative DisordersNeuroprotectionAmyloid InhibitionAnimal Disease ModelsAstrocyte ResponseDeferoxamine PharmacologyFerritin RegulationFerritin-mediated Iron RegulationIron Metabolism In GliaNeuroprotective Agents
Lipocalin 2 (Lcn2) has been implicated to play a role in various neurodegenerative diseases, and normalizing its overexpression may be of therapeutic potential. Iron chelators were found to reduce Lcn2 levels in certain animal models of CNS injury. Focusing on Alzheimer's disease (AD), we found that the iron chelators deferoxamine and deferiprone inhibited amyloid-β (Aβ)-induced Lcn2 production in cultured primary astrocytes. Accordingly, Aβ-exposure increased astrocytic ferritin production, indicating the possibility that Aβ induces iron accumulation in astrocytes. This effect was not significantly modulated by Lcn2. Known neuroprotective effects of iron chelators may rely in part on normalization of Lcn2 levels.
19
Structural conversion of neurotoxic amyloid-β1–42 oligomers to fibrils
Mahiuddin Ahmed, Judianne Davis, Darryl Aucoin et al. · Nature Structural & Molecular Biology · 2010 · 1.1K citations · Full text
Thorsten Berger, Atsushi Togawa, Gordon S. Duncan et al. · Proceedings of the National Academy of Sciences · 2006 · 470 citations · Full text
Pamela J. Urrutia, Pabla Aguirre, Andrés Esparza et al. · Journal of Neurochemistry · 2013 · 361 citations · Full text
Medicine, Neurobiology, Neuroscience +15
Lipocalin 2: Novel component of proinflammatory signaling in Alzheimer's disease
Petrus J.W. Naudé, Csaba Nyakas, Lee E. Eiden et al. · The FASEB Journal · 2012 · 211 citations · Full text